NCT05085496
Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
StatusActive, Not Recruiting
PhasePhase 1
SponsorCity of Hope Medical Center
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 9 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 26 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 2 of 3 entries
- Site details revised
- Minor Primary completion date: Aug 10, 2027 to Sep 10, 2027v10
- Notable Primary completion date: Dec 1, 2024 to Aug 10, 2027
- Study completion date: Dec 1, 2024 to Sep 10, 2027
- Minor Start date changed from estimate of Jul 15, 2022 to Apr 19, 2022v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
Show 3 earlier versionsHide 3 earlier versions
- Notable Primary and study completion dates: Dec 1, 2023 to Dec 1, 2024
- Start date: Dec 30, 2021 to Jul 15, 2022
- Minor Collaborators: 1 to 2
- Study title shortened, about 2 words
- Notable Start date: Nov 1, 2021 to Dec 30, 2021v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Dose limiting toxicity
Timeframe: Up to 3 weeks
Incidence of adverse events
Timeframe: Up to 90 days
Secondary (3)
Treatment response rate
Overall survival (OS)
Progression free survival (PFS)
Arms and interventions
Treatment (SBRT, atezolizumab)Experimental
Patients undergo SBRT on days 1, 3, 5, 7, and 9 of cycle 1. Beginning 1-2 days after SBRT, patients also receive atezolizumab IV on day 1. Treatment repeats every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity.
Biologicals: Atezolizumab
Radiation: Stereotactic Body Radiation Therapy
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States